<DOC>
	<DOCNO>NCT01808157</DOCNO>
	<brief_summary>This Phase II , multi-centre , randomise , double-blind , placebo-controlled study male female subject , age ≥ 12 year mild/moderate atopic dermatitis least moderate pruritus . All subject receive BID topical application CT327 ointment vehicle 4 week . At baseline , subject must atopic dermatitis , define Hanifin Rajka criterion , involve minimum 5 % maximum 20 % body surface area , Investigator Global Assessment Score 2 3 ( mild moderate ) pruritus visual analogue scale score ≥ 40mm ( least moderate ) . All subject attend screen visit 21 day prior Day 1 . Subjects require return clinic Days 1 ( baseline visit ) , 4 , 11 , 18 29 ( end treatment visit ) . All subject ask attend follow-up visit 14 ( ±3 ) day last dose study medication .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety Tolerability CT327 Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female subject age ≥ 12 year . Clinical diagnosis atopic dermatitis ( define Hanifin Rajka criterion ( Appendix F ) screening : IGA score 2 3 ( mild moderate ) Score ≥ 40mm screen pruritus VAS assessment ( average worst last 24 hour current itch ) A minimum 5 % 20 % subject ' BSA affect atopic dermatitis ( affected define active atopic dermatitis lesion pruritus ) Amenable treatment topical treatment Stable disease ≥1 month prior screen Atopic dermatitis affect head scalp . Unstable actively infect atopic dermatitis . Concomitant dermatologic medical condition ( ) may interfere investigator 's ability evaluate subject 's response study drug . Subjects received monoclonal antibody therapy atopic dermatitis 4 month prior screen . Subjects use systemic immunosuppressive drug , corticosteroid receive PUVA therapy 4 week prior start study treatment , schedule start treatment study period . Subjects use topical immunomodulators ( pimecrolimus , tacrolimus ) within 2 week start study treatment schedule start treatment study period . Subjects use topical corticosteroid WHO group II , III IV , treatment atopic dermatitis , include wet wrap , within 2 week prior start study treatment likely require treatment medication study period . Subjects unable abstain use emollient baseline ( Visit 2 ) end study treatment ( Visit 6 ) . Subjects use concomitant medication ( ) , investigator ' opinion , could affect subject 's atopic dermatitis pruritus ( example TADs , SSRI , pregabalin ) . Subjects use medication may include , investigator discretion , stable treatment least 1 month prior start study treatment change medication plan study period . Subjects undergoing , due , UVA , UVB therapy 2 week prior start study treatment study period . Planned exposure affect area excessive sunlight . Subjects clinically significant abnormal laboratory safety test and/or 12lead ECG result screen . Subjects receive investigational drug take part clinical study investigational drug within three month prior start study treatment . Subjects know reaction allergy test drug excipients .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>atopic dermatitis</keyword>
	<keyword>pruritus</keyword>
</DOC>